Design of Alendronate sodium [Design Issues]

posted by raghavendra_s – 2010-05-12 13:16 (5886 d 22:42 ago) – Posting: # 5332
Views: 4,858

Dear Madam/Sir,

I would like to know the issues involved in the design of Alendronate sodium for two treatment, two period, two sequence, single dose, crossover bioequivalence study.

Please clarify me the issues associated with sampling (plasma/serum or urine)? which one is best to quantify the drug, serum/plasma or urine? How it impact the study design?

In the published literature, the number of volunteers too largely vary from one article to another. How much sample size is required? statistical parameters etc. What is the washout period for this study ?

It seems only HPLC-Fluorescence detection technique is available for estimation of the drug. Is there any updates on analytical developments of this drug in serum?

Any discussion on further updates, technical aspects on this study design is highly appreciated?

Kind regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
123 visitors (0 registered, 123 guests [including 11 identified bots]).
Forum time: 11:58 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5